About Nexus BioPharma, Inc
In completed pre-clinical trials of the pharmaceutical activation of this pathway, test subjects showed reduced fat mass and a higher rate of energy expenditure. Subjects also showed increased insulin sensitivity, increased fatty acid oxidation, improved plasma and tissue triglyceride levels, with lower cholesterol.
Upon translation of this pharmaceutical activation to humans, these effects are expected to have a significant impact on obesity and diabetes. Nexus BioPharma is now advancing to pre-IND trials in preparation for FDA human trials.